TP53 and cancer: The team first demonstrated that p53-driven ferroptosis independent of GPX4 in response to ROS-induced ferroptosis and subsequently revealed that loss of iPLA2β expression significantly increased the sensitivity of cancer cells to p53-dependent ferroptosis in response to ROS-induced ferroptosis.